open access

Vol 5, No 4 (2020)
Invited editorial
Published online: 2020-10-15
Get Citation

Levosimendan comes of age: twenty years in clinical use

F. Guarracino1, J. Alvarez2, D. Bettex3, S. Bouchez4, S. Fruhwald5, M. Girardis6, M. Heringlake7, A. Herpain8, S. E. Ricksten9, W. Toller5
·
Medical Research Journal 2020;5(4):219-221.
Affiliations
  1. Dipartimento di Anestesia e Terapie Intensive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
  2. Department of Anesthesia and Surgical ICU, University of Santiago de Compostela, Santiago de Compostela, Spain
  3. Cardiac Anaesthesia, University Hospital, Zürich, Switzerland
  4. Department of Anesthesiology, University Hospital, Ghent, Belgium
  5. Department of Anaesthesiology and Intensive Care Medicine, Division of Anaesthesiology for Cardiovascular Surgery and Intensive Care Medicine, Medical University of Graz, Graz, Austria
  6. Struttura Complessa di Anestesia 1, Policlinico di Modena, Modena, Italy
  7. Klinik für Anästhesiologie und Intensivmedizin, Universität zu Lübeck, Lübeck, Germany
  8. Department of Intensive Care, Erasme University Hospital, Brussels, Belgium
  9. Department of Anesthesiology and Intensive Care, Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden

open access

Vol 5, No 4 (2020)
INVITED EDITORIALS
Published online: 2020-10-15

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

critical care, calcium sensitization, levosimendan, KATP channels, weaning, sepsis

About this article
Title

Levosimendan comes of age: twenty years in clinical use

Journal

Medical Research Journal

Issue

Vol 5, No 4 (2020)

Article type

Invited editorial

Pages

219-221

Published online

2020-10-15

Page views

559

Article views/downloads

614

DOI

10.5603/MRJ.a2020.0036

Bibliographic record

Medical Research Journal 2020;5(4):219-221.

Keywords

critical care
calcium sensitization
levosimendan
KATP channels
weaning
sepsis

Authors

F. Guarracino
J. Alvarez
D. Bettex
S. Bouchez
S. Fruhwald
M. Girardis
M. Heringlake
A. Herpain
S. E. Ricksten
W. Toller

References (16)
  1. Tritapepe L, Pollesello P, Grossini E. The inodilator levosimendan: 20 years of experience in various settings of cardiac care. Med Res J. 2020; 5(3): 1–2.
  2. Papp Z, Édes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012; 159(2): 82–87.
  3. Li H, Duan Y, Chen B, et al. New pharmacological treatments for heart failure with reduced ejection fraction (HFrEF): A Bayesian network meta-analysis. Medicine (Baltimore). 2020; 99(5): e18341.
  4. Sanfilippo F, Knight JB, Scolletta S, et al. Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery: a systematic review and meta-analysis. Crit Care. 2017; 21(1): 252.
  5. Herpain A, Bouchez S, Girardis M, et al. Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper. J Cardiovasc Pharmacol. 2019; 73(1): 3–14.
  6. Lim JuY, Deo SV, Rababa'h A, et al. Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. J Card Surg. 2015; 30(7): 547–554.
  7. Guarracino F, Heringlake M, Cholley B, et al. Use of Levosimendan in Cardiac Surgery: An Update After the LEVO-CTS, CHEETAH, and LICORN Trials in the Light of Clinical Practice. J Cardiovasc Pharmacol. 2018; 71(1): 1–9.
  8. van Diepen S, Mehta RH, Leimberger JD, et al. Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. J Thorac Cardiovasc Surg. 2020; 159(6): 2302–2309.e6.
  9. Yilmaz MB, Grossini E, Silva Cardoso JC, et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther. 2013; 27(6): 581–590.
  10. Gordon A, Santhakumaran S, Al-Beidh F, et al. Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Efficacy and Mechanism Evaluation. 2018; 5(6): 1–94.
  11. Sangalli F, Bellani G, Affronti A, et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients: current evidence and future directions. Minerva Anestesiol. 2020; 86(6): 645–651.
  12. Roesthuis L, van der Hoeven H, Sinderby C, et al. Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation. Intensive Care Med. 2019; 45(10): 1372–1381.
  13. Distelmaier K, Roth C, Schrutka L, et al. Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016; 117(1): 52–58.
  14. Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013; 41(10): 2328–2335.
  15. Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential Effects of Levosimendan and Dobutamine on Glomerular Filtration Rate in Patients With Heart Failure and Renal Impairment:A Randomized Double-Blind Controlled Trial. J Am Heart Assoc. 2018; 7(16): e008455.
  16. Lannemyr L, Bragadottir G, Redfors B, et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. J Crit Care. 2020; 57: 225–230.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl